CN202235772U - Artificial lens - Google Patents
Artificial lens Download PDFInfo
- Publication number
- CN202235772U CN202235772U CN2011203613146U CN201120361314U CN202235772U CN 202235772 U CN202235772 U CN 202235772U CN 2011203613146 U CN2011203613146 U CN 2011203613146U CN 201120361314 U CN201120361314 U CN 201120361314U CN 202235772 U CN202235772 U CN 202235772U
- Authority
- CN
- China
- Prior art keywords
- triamcinolone acetonide
- release agent
- acetonide acetate
- artificial
- acetate nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- VOBDXTSTTMAKHK-VHDCPBDGSA-N 3870-07-3 Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O VOBDXTSTTMAKHK-VHDCPBDGSA-N 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 14
- 239000013078 crystal Substances 0.000 abstract description 3
- 238000013268 sustained release Methods 0.000 abstract 3
- 239000012730 sustained-release form Substances 0.000 abstract 3
- 206010036346 Posterior capsule opacification Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 11
- 208000002177 Cataract Diseases 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 3
- 206010011732 Cyst Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000001542 lens epithelial cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Prostheses (AREA)
Abstract
The utility model relates to an artificial lens containing a triamcinolone acetonide acetate nano sustained-release agent. The artificial lens comprises an artificial crystal loop and is characterized in that: a medicine bag is arranged on the artificial crystal loop; and the triamcinolone acetonide acetate nano sustained-release agent is inlaid into the medicine bag. The utility model provides the artificial lens containing the triamcinolone acetonide acetate nano sustained-release agent, which can effectively avoid posterior capsule opacification and is simple to prepare and convenient to use.
Description
Technical field
This utility model belongs to field of medicaments, relates to a kind of intraocular lens, relates in particular to a kind of intraocular lens of containing this triamcinolone acetonide acetate nano slow release agent.
Background technology
Cataract is global the first blinding property oculopathy.The cataract capsule extracts the main means that associating posterior chamber intraocular lens implantation has become curing cataract outward.Complete back cyst membrane not only played supporting role to posterior chamber intraocular lens, also reduced the incidence rate of postoperative detachment of retina, CME, endophthalmitis.But the back capsule muddiness that muddiness, the fibrosis of postoperative posterior lens capsule film cause is the primary complication of extracapsular extraction of cataract, becomes the primary factor of visual deterioration at a specified future date.The propagation of the muddy lens epithelial cell of back capsule, divide a word with a hyphen at the end of a line and fibrosis has played important function in the muddy generation of back capsule.Although its prevention and treatment more and more receive ophthalmologist's concern, do not find the appropriate measure that addresses this problem at present as yet.At present, it is main still cutting with cyst membrane behind the laser.Therefore, seek the muddy effective and medicine that have no side effect of control back capsule very big meaning is arranged.Triamcinolone acetonide acetate is a kind of long-acting glucocorticoid, and it has powerful antiinflammatory, anti-allergy action, and effect is strong and lasting, is widely used clinically.Yet if long-term whole body uses glucocorticoid can produce complication and toxic and side effects, during topical application, because the drug metabolism elimination is fast, bioavailability is low, drug effect is of short duration, often needs multiple dosing.When ophthalmic applications, may produce other complication, and reduce patient's toleration owing to multiple dosing.Therefore, the improvement of new hormone dosage form and medication has very big exploration to be worth.
The utility model content
In order to solve the above-mentioned technical problem that exists in the background technology, this utility model provides a kind of can effectively prevent muddy, the preparation process intraocular lens of containing the triamcinolone acetonide acetate nano slow release agent simple, easy to use of back capsule.
The technical solution of this utility model is: this utility model provides a kind of intraocular lens of containing the triamcinolone acetonide acetate nano slow release agent, comprises that the artificial intraocular lenses fastens with a rope, string, etc., and its special character is: said artificial intraocular lenses's button loop is provided with medicine bag; Be inlaid with the triamcinolone acetonide acetate nano slow release agent in the said medicine bag.
Above-mentioned medicine bag socket or be connected on artificial intraocular lenses's button loop.
Above-mentioned artificial intraocular lenses's button loop is one or more.
The utility model has the advantages that:
The method for preparing of the triamcinolone acetonide acetate nano slow release agent that the new prevention postcataract inflammation that this utility model provided and back capsule are muddy and contain the intraocular lens of this slow releasing agent; At first triamcinolone acetonide acetate is prepared with poly lactic coglycolic acid (PLGA) carrier material and become nanoparticle; Improved triamcinolone acetonide acetate bioavailability and release stability and in water dissolubility; And it is made as the disc-shaped structure of the about 1-3mm of diameter; Climb up so that be enclosed within the intraocular lens, together implant in the lens capsule bag, can simplify the administering mode of postoperative with the artificial intraocular lenses; Be convenient to bring into play triamcinolone acetonide acetate anti-inflammatory, inhibition of cell proliferation, possibly be able to prevent and treat the muddiness of back capsule.
Description of drawings
Fig. 1 is the intraocular lens's of containing the triamcinolone acetonide acetate nano slow release agent that this utility model provided sketch map.
The specific embodiment
Referring to Fig. 1; This utility model provides a kind of intraocular lens of containing the triamcinolone acetonide acetate nano slow release agent; It comprises that intraocular lens optic portion 1 and the artificial intraocular lenses who links to each other with intraocular lens optic portion 1 fasten with a rope, string, etc. 2; Different with the conventional artificial crystal is, the artificial intraocular lenses that this utility model provided fastens with a rope, string, etc. and 2 is provided with and is used for medicine bag 3; Be inlaid with the triamcinolone acetonide acetate nano slow release agent in the medicine bag 3, medicine bag 3 sockets or be connected to the artificial intraocular lenses and fasten with a rope, string, etc. on 2.It 2 is one or more that the artificial intraocular lenses fastens with a rope, string, etc.But pushing away through the artificial intraocular lenses with the artificial intraocular lenses in this utility model Rhizoma Atractylodis Macrocephalae helps device together to implant in the lens capsule bag.
Claims (3)
1. intraocular lens of containing the triamcinolone acetonide acetate nano slow release agent comprises that the artificial intraocular lenses fastens with a rope, string, etc., and is characterized in that: said artificial intraocular lenses's button loop is provided with medicine bag; Be inlaid with the triamcinolone acetonide acetate nano slow release agent in the said medicine bag.
2. the intraocular lens of containing the triamcinolone acetonide acetate nano slow release agent according to claim 1 is characterized in that: said medicine bag socket or be connected on artificial intraocular lenses's button loop.
3. the intraocular lens of containing the triamcinolone acetonide acetate nano slow release agent according to claim 1 and 2 is characterized in that: said artificial intraocular lenses's button loop is one or more.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011203613146U CN202235772U (en) | 2011-09-26 | 2011-09-26 | Artificial lens |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011203613146U CN202235772U (en) | 2011-09-26 | 2011-09-26 | Artificial lens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN202235772U true CN202235772U (en) | 2012-05-30 |
Family
ID=46097088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011203613146U Expired - Fee Related CN202235772U (en) | 2011-09-26 | 2011-09-26 | Artificial lens |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN202235772U (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103156708A (en) * | 2013-02-01 | 2013-06-19 | 浙江大学医学院附属第二医院 | Artificial lens with drug sustained release micro-capsules inlaid on loop and manufacturing method thereof |
| CN106901871A (en) * | 2015-12-23 | 2017-06-30 | 爱博诺德（北京）医疗科技有限公司 | Intraocular lens with one or more extentions |
-
2011
- 2011-09-26 CN CN2011203613146U patent/CN202235772U/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103156708A (en) * | 2013-02-01 | 2013-06-19 | 浙江大学医学院附属第二医院 | Artificial lens with drug sustained release micro-capsules inlaid on loop and manufacturing method thereof |
| CN106901871A (en) * | 2015-12-23 | 2017-06-30 | 爱博诺德（北京）医疗科技有限公司 | Intraocular lens with one or more extentions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022130379A (en) | Devices and methods for continuous drug delivery via mouth | |
| WO2014165308A3 (en) | Microsphere drug delivery system for sustained intraocular release | |
| WO2013022783A3 (en) | Progesterone containing oral dosage forms and related methods | |
| BRPI0516308A2 (en) | fluid composition, methods of treating a disease or dysfunction, methods of local or systemic release of a biological agent, implants, method of forming an implant, biological agent kit and uses of a fluid composition | |
| CN203220483U (en) | Artificial-crystal drug releasing apparatus capable of opening by laser | |
| WO2017037593A2 (en) | Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition | |
| CN202235772U (en) | Artificial lens | |
| CN101401791A (en) | Timolol liposome and preparation method thereof | |
| CN103622903A (en) | Propranolol hydrochloride lipidosome gel and preparation method thereof | |
| RU2016120644A (en) | ELECTRIC MATRIX AND ITS APPLICATIONS | |
| CN115737782A (en) | Microneedle patch carrying melittin nanoparticles and/or antigens, preparation method and application | |
| CN100522162C (en) | New pranoprofen eye drops and its preparation method | |
| CN102327212A (en) | Triamcinolone acetonaide acetate nano controlled-release formulation, preparation method thereof and artificial lens containing same | |
| CN110812420B (en) | Traditional Chinese medicine composition for treating oral ulcer, traditional Chinese medicine film agent, preparation method and application | |
| CN101491532B (en) | Erigeron breviscapus eye-preparation and preparation method thereof | |
| CN101703463A (en) | Paracetamol temperature sensitive gel and preparation method and application thereof | |
| CN107397745A (en) | Azole compounds eye-drops preparations | |
| CN103169548A (en) | Drug-carrying type artificial lens capable of being opened by laser | |
| CN200973766Y (en) | Artificial lentis for preventing disease after cataract operation | |
| CN104825426A (en) | Double-phase melatonin patch | |
| CN106955288A (en) | Purposes of the FXR activators in treatment embryonal-cell lipoma relevant disease medicine is prepared | |
| CN100579576C (en) | Entoptic embedding material for preventing aggravation of nearsightedness | |
| Rewar et al. | Pulsatile drug delivery release technologies: An overview | |
| CN103945832B (en) | For brain kinetomeres sustained release and the compositionss of sustained release, device and method | |
| CN102198087B (en) | Preservative-free ophthalmic in-situ gelling agent and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: SUN LIHUA Effective date: 20150731 Owner name: THE 4TH MILITARY SURGEON UNIV. P. L. A. Free format text: FORMER OWNER: YAN HONG Effective date: 20150731 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150731 Address after: 710032 Changle West Road, Shaanxi, No. 169 West Road, The Fourth Military Medical University, Patentee after: The Fourth Military Medical University of the Chinese People's Liberation Army Address before: 710038 Tangdu Hospital, 1 Temple Road, Baqiao District, Shaanxi, Xi'an, China Patentee before: Yan Hong Patentee before: Sun Lihua |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120530 Termination date: 20160926 |